Type of security: Stock
Sector: Health Care
The data is delayed by 15 minutes.
CRL is in the long-term up 86% in 5 years.
Description: Charles River Laboratories International, Inc., together with its subsidiaries, provides research models and associated services, and outsourced preclinical services to accelerate the drug discovery and development process. It operates through two segments, Research Models and Services (RMS), and Preclinical Services (PCS). The RMS segment produces and sells research model strains, principally genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also offers a range of services to assist customers in the drug discovery and development process, which include genetically engineered models and services, insourcing solutions, discovery research services, and research animal diagnostic services; endotoxin and microbial detection products and services; and avian vaccine products and services. The PCS segment provides preclinical services, including in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program manage
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-6.09%||Sales Growth - Q/Q||-2.77%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||6.9%||ROE||18.39%||ROI||8.26%|
|Current Ratio||2.27||Quick Ratio||1.95||Long Term Debt/Equity||2.2||Debt Ratio||0.39|
|Gross Margin||36.67%||Operating Margin||13.72%||Net Profit Margin||9.67%||Dividend Payout Ratio|
|Cash From Financing Activities||-63.73 M||Cash From Investing Activities||-36.49 M||Cash From Operating Activities||96.68 M||Gross Profit||132.78 M|
|Net Profit||48.51 M||Operating Profit||55.73 M||Total Assets||1.89 B||Total Current Assets||629.65 M|
|Total Current Liabilities||276.53 M||Total Debt||772.77 M||Total Liabilities||1.18 B||Total Revenue||339.57 M|
|High 52 week||148.55||Low 52 week||104.82||Last close||132.6||Last change||-1.63%|
|RSI||44.11||Average true range||4.13||Beta||0.74||Volume||208.32 K|
|Simple moving average 20 days||-2.2%||Simple moving average 50 days||-1.84%||Simple moving average 200 days||0.51%|
|Performance Week||-0.39%||Performance Month||-2.86%||Performance Quart||-2.89%||Performance Half||5.72%|
|Performance Year||8.46%||Performance Year-to-date||17.16%||Volatility daily||2.02%||Volatility weekly||4.52%|
|Volatility monthly||9.26%||Volatility yearly||32.08%||Relative Volume||241.93%||Average Volume||337.28 K|
|New High||New Low|
2019-10-16 16:30:00 | Charles River Laboratories Demonstrates Industry-Leading Research at Neuroscience 2019
2019-10-15 12:35:55 | Is Charles River Laboratories International Inc. CRL Going To Burn These Hedge Funds ??
2019-10-09 09:18:34 | Calculating The Fair Value Of Charles River Laboratories International, Inc. NYSE:CRL
2019-10-08 10:36:02 | LabCorp LH Names Two Leaders for Major Business Wings
2019-10-01 08:00:00 | Charles River Laboratories Adds Virginia M. Wilson to Board of Directors
2019-09-09 08:00:00 | Charles River Laboratories Announces Updates to Microbial Solutions Product Portfolio
2019-09-05 16:30:00 | Charles River Laboratories to Host 3rd Annual World Congress
2019-09-04 09:00:01 | What Makes Charles River CRL a New Buy Stock
2019-09-03 16:30:00 | Charles River Laboratories to Present at Baird and Morgan Stanley Investor Conferences
2019-08-12 10:14:25 | Is Charles River Laboratories International NYSE:CRL A Risky Investment?
2019-08-02 03:40:30 | Edited Transcript of CRL earnings conference call or presentation 31-Jul-19 12:30pm GMT
2019-08-01 02:17:51 | Blue-blooded crabs at heart of pharma dispute on drug testing
2019-08-01 02:00:00 | FOCUS-Blue-blooded crabs at heart of pharma dispute on drug testing
2019-07-31 19:23:38 | Charles River Laboratories International Inc CRL Q2 2019 Earnings Call Transcript
2019-07-31 08:25:12 | Charles River Laboratories CRL Q2 Earnings Beat Estimates
2019-07-31 07:00:00 | Charles River Laboratories Announces Second-Quarter 2019 Results
2019-07-30 11:45:03 | Healthcare Stock Q2 Earnings Due on Jul 31: HUM, AMED & More
2019-07-24 10:32:02 | Earnings Preview: Charles River Laboratories CRL Q2 Earnings Expected to Decline
2019-06-20 13:33:16 | Is Charles River Laboratories International Inc. CRL A Good Stock To Buy?
2019-06-14 15:02:00 | Don't Jump Into Charles River Labs Just Yet
2019-05-16 08:00:00 | Charles River Laboratories Invests in Resero Analytics™
2019-05-07 17:00:26 | Edited Transcript of CRL earnings conference call or presentation 7-May-19 12:30pm GMT
2019-05-07 16:13:18 | Medical Stock Pummeled On China Trade Worries — Wiping Out Earnings Beat
2019-05-07 15:23:43 | Charles River Laboratories International Inc CRL Q1 2019 Earnings Call Transcript
2019-05-07 08:15:12 | Charles River Laboratories CRL Beats Q1 Earnings and Revenue Estimates
2019-05-07 07:11:34 | Charles River: 1Q Earnings Snapshot
2019-05-07 07:00:00 | Charles River Laboratories Announces First-Quarter 2019 Results
2019-04-30 14:39:45 | Charles River Labs says its biotech, pharma clients' data was hacked
2019-04-30 10:32:02 | Charles River Laboratories CRL Q1 Earnings Preview: What's in the Cards?
2019-04-29 07:00:00 | Charles River Laboratories Completes the Acquisition of Citoxlab
2019-04-22 13:12:40 | Were Hedge Funds Right About Piling Into Charles River Laboratories International CRL?
2019-04-12 11:52:03 | Top Ranked Growth Stocks to Buy for April 12th
2019-04-12 10:32:02 | Teladoc's Partnership to Form Pediatric Telehealth Platform